Management of immunotherapy toxicities in older adults
- PMID: 30446167
- DOI: 10.1053/j.seminoncol.2018.09.001
Management of immunotherapy toxicities in older adults
Abstract
Advanced age is a risk factor for cancer and is attributed to dysregulation of the immune system. Historically, treatment of advanced cancer has primarily involved systemic chemotherapy that is associated with high treatment related toxicity especially in older adults. Immune checkpoint inhibitors (ICIs) provide an exciting treatment option for older adults in terms of efficacy and safety as compared to systemic chemotherapy. Given the pace of approval of ICIs for multiple cancers, there is an increase in both the use of ICIs and the associated immune-related adverse events. In this article, we address how to approach immunotherapy related toxicities in older adults given the availability of limited data.
Keywords: Immune checkpoint inhibitors; Immune-related adverse events; Older adults.
Copyright © 2018 Elsevier Inc. All rights reserved.
Similar articles
-
Immunotherapy Toxicities.Surg Oncol Clin N Am. 2019 Jul;28(3):387-401. doi: 10.1016/j.soc.2019.02.009. Epub 2019 Apr 5. Surg Oncol Clin N Am. 2019. PMID: 31079795 Review.
-
New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity.J Natl Compr Canc Netw. 2018 May;16(5S):594-596. doi: 10.6004/jnccn.2018.0047. J Natl Compr Canc Netw. 2018. PMID: 29784734
-
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.Nat Rev Clin Oncol. 2019 Sep;16(9):563-580. doi: 10.1038/s41571-019-0218-0. Nat Rev Clin Oncol. 2019. PMID: 31092901 Review.
-
Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.J Emerg Med. 2018 Oct;55(4):489-502. doi: 10.1016/j.jemermed.2018.07.005. Epub 2018 Aug 16. J Emerg Med. 2018. PMID: 30120013 Review.
-
A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.J Natl Compr Canc Netw. 2019 Jun 1;17(6):712-720. doi: 10.6004/jnccn.2018.7268. J Natl Compr Canc Netw. 2019. PMID: 31200355
Cited by
-
A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.J Med Toxicol. 2021 Oct;17(4):411-424. doi: 10.1007/s13181-021-00833-8. Epub 2021 Apr 7. J Med Toxicol. 2021. PMID: 33826117 Free PMC article. Review.
-
Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features.Front Immunol. 2022 Apr 5;13:875093. doi: 10.3389/fimmu.2022.875093. eCollection 2022. Front Immunol. 2022. PMID: 35479081 Free PMC article.
-
Baseline risk factors associated with immune related adverse events and atezolizumab.Front Oncol. 2023 Feb 28;13:1138305. doi: 10.3389/fonc.2023.1138305. eCollection 2023. Front Oncol. 2023. PMID: 36925916 Free PMC article.
-
Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer.Expert Rev Anticancer Ther. 2022 Aug;22(8):861-874. doi: 10.1080/14737140.2022.2094772. Epub 2022 Jul 4. Expert Rev Anticancer Ther. 2022. PMID: 35786142 Free PMC article. Review.
-
Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders.Oncologist. 2020 Jun;25(6):e946-e954. doi: 10.1634/theoncologist.2020-0035. Epub 2020 Mar 17. Oncologist. 2020. PMID: 32181960 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
